RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven ...
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made ...
Oncogenic RAS mutations are common in multiple myeloma (MM), an incurable malignancy of plasma cells. However, the mechanisms of pathogenic RAS signaling in this disease remain enigmatic and difficult ...
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...
Latest Parallels RAS release delivers expanded Nutanix, Azure, and Azure Virtual Desktop capabilities, greater infrastructure flexibility, and improved browser-based user experiences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results